MktsMarkets

Ligand Pharmaceuticals Incorporated
NASDAQ: LGNDKey statistics
LGND News
Stories mentioning LGND from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 51,722 | 59,666 | 115,461 | 47,627 | 45,333 | 42,812 | 51,812 | 41,531 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 2,148 | 3,511 | 21,019 | 6,567 | 50,085 | 4,425 | 5,675 | 5,354 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 17,368 | 13,843 | 54,931 | 8,444 | (36,216) | (9,637) | 3,143 | (19,100) |
| Interest Income | 6,655 | 6,393 | 3,874 | 1,621 | 1,771 | 1,931 | 1,347 | 2,757 |
| Interest Expense | ||||||||
| Other Expense | (1,175) | 1,483 | (443.00) | 1,372 | (2,501) | 24,864 | (9,466) | (33,523) |
| Pretax Income | (24,259) | 56,780 | 141,137 | 11,223 | (50,180) | (39,200) | (6,339) | (65,390) |
| Tax Provision | (10,914) | 11,996 | 23,864 | 6,376 | (7,729) | (8,112) | 833.00 | (13,479) |
| Net Income (Loss) | (13,345) | 44,784 | 117,273 | 4,847 | (42,451) | (31,088) | (7,172) | (51,911) |
| Earnings Per Share (Basic) | (0.67) | 2.32 | 5.99 | 0.25 | (2.21) | (1.70) | (0.39) | (2.88) |
| Earnings Per Share (Diluted) | (0.67) | 2.21 | 5.68 | 0.24 | (2.21) | (1.70) | (0.39) | (2.88) |
| Weighted Average Shares Outstanding (Basic) | 19,883 | 19,338 | 19,578 | 19,327 | 19,191 | 18,290 | 18,419 | 18,028 |
| Weighted Average Shares Outstanding (Diluted) | 19,883 | 20,294 | 20,629 | 19,926 | 19,191 | 18,290 | 18,419 | 18,028 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About LGND
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a stock listed on the Nasdaq Stock Market under the ticker symbol LGND. It last traded at $286.85 (Nov 20, 2026, 4:00 PM ET), down 0.0% on the day. That gives Ligand Pharmaceuticals a market capitalisation of $5.7B and a price-to-earnings ratio of 111.5.
Over the past 52 weeks LGND has traded between $175.89 and $326.63.
Revenue for the quarter ended Mar 31, 2026 was $51.7M; a net loss of $13.3M. Revenue was up 14.1% from $45.3M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $51.7M | -$13.3M | -25.8% |
| Dec 31, 2025 | $59.7M | $44.8M | 75.1% |
| Sep 30, 2025 | $115.5M | $117.3M | 101.6% |
| Jun 30, 2025 | $47.6M | $4.8M | 10.2% |
From Ligand Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…